The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Nonserious Infection Rates with Biologics Used to Treat RA

Nonserious Infection Rates with Biologics Used to Treat RA

September 27, 2021 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Introduction & Objectives

Patients with rheumatoid arthritis (RA) experience a greater number of infections than the general population. These infections are frequent and contribute to substantial morbidity and mortality. Susceptibility to infection is related to a combination of disease-related immunologic dysfunction, immunocompromising comorbidities and the use of immunomodulatory drugs. It is also determined by patient lifestyle and other factors.

You Might Also Like
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Investigators Assess Infection Risk with RA Biologics
  • Infection Rates for Patients with SLE on Immunosuppressive Drugs

Nonserious infections, defined as events managed outside a hospital admission, have been reported in 20–30% of patients with RA each year and are the most common adverse events in large clinical trials. In elderly patients with RA, nonserious infection rates are estimated at 47.5 per 100 patient-years. Although these events are not life-threatening, their burden is high and recurrent nonserious infections may lead to variable periods of treatment discontinuation. Meta-analyses of data on immune-mediated inflammatory diseases have suggested differences in the risk of nonserious infections between tumor necrosis factor inhibitor agents, but the impact of other bDMARDs and the predictors of such risk are less well understood.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across bDMARDs within the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA).

Methods

The BSRBR-RA is a prospective observational cohort study. A nonserious infection was defined as one that did not require hospitalization or intravenous therapy. Infections were captured from clinician questionnaires and patient diaries. Individuals were considered at risk from the date of initiation of biologic treatment for up to three years. Drug exposure was defined by agent: tumor necrosis factor (TNF) inhibitors, interleukin-6 (IL-6) inhibitors, B cell depletion agent (rituximab) or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) alone. A multiple-failure Cox model was used with multivariable adjustment. Missing data were addressed using multiple imputation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results

During the study period, 8,145 patients experienced 17,304 nonserious infections, with an event rate of 27.0 per person per year (95% confidence interval [95% CI] 26.6–27.4). Increasing age, female sex, comorbidity, glucocorticoid therapy, higher Disease Activity Score in 28 joints and higher Health Assessment Questionnaire disability index were associated with an increased risk of nonserious infection.

The data revealed a significant reduction in the risk of nonserious infection with csDMARDs compared with bDMARDs.

Compared with TNF inhibitors, IL-6 inhibition and rituximab were associated with a higher risk of nonserious infection (adjusted HR 1.45 [95% CI 1.29–1.63] and adjusted HR 1.28 [95% CI 1.14–1.45], respectively), and the csDMARD cohort had a lower risk (adjusted HR 0.64 [95% CI 0.59–0.70]). Within the TNF inhibitor class, adalimumab was associated with a higher nonserious infection risk than etanercept (adjusted HR 1.11 [95% CI 1.05–1.17]).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Conclusion

Nonserious infections occur frequently in patients with RA, and predictors mirror those reported with serious infections. All bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large, and a relationship between nonserious infection and targeted immunomodulatory therapy likely exists.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis & Rheumatology, biologic disease-modifying antirheumatic drugs, biologic DMARD, Infection, RA Resource Center, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Investigators Assess Infection Risk with RA Biologics
  • Infection Rates for Patients with SLE on Immunosuppressive Drugs
  • Rheumatoid Arthritis May Confer Higher Cardiac & Infection Risks

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)